Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
103.58
+5.80 (5.93%)
At close: May 12, 2025, 4:00 PM
103.38
-0.20 (-0.19%)
After-hours: May 12, 2025, 7:23 PM EDT
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuroscience | 2.72B | 2.70B | 2.66B | 2.63B | 2.64B | 2.71B | 2.76B | 2.80B | ||||||||||
| Neuroscience Growth | 3.25% | -0.35% | -3.68% | -5.92% | -5.85% | -1.92% | 1.99% | 5.89% | ||||||||||
| Oncology | 1.08B | 1.11B | 1.09B | 1.07B | 1.04B | 1.02B | 965.36M | 928.30M | ||||||||||
| Oncology Growth | 3.77% | 9.47% | 13.26% | 15.16% | 15.23% | 16.18% | 12.64% | 13.42% |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rylaze Enrylaze | 402.33M | 410.85M | 411.11M | 417.19M | 411.05M | 394.23M | 373.45M | 342.11M | ||||||||||
| Rylaze Enrylaze Growth | -2.12% | 4.22% | 10.08% | 21.95% | 31.17% | 39.97% | 40.58% | 60.76% | ||||||||||
| Zepzelca | 308.25M | 320.32M | 316.00M | 308.15M | 297.45M | 289.53M | 287.49M | 279.82M | ||||||||||
| Zepzelca Growth | 3.63% | 10.63% | 9.92% | 10.13% | 7.09% | 7.27% | 9.40% | 5.92% | ||||||||||
| Defitellio Defibtrotide | 209.55M | 216.57M | 210.00M | 191.91M | 192.60M | 184.00M | 173.57M | 175.29M | ||||||||||
| Defitellio Defibtrotide Growth | 8.80% | 17.70% | 20.99% | 9.48% | 4.74% | -5.30% | -11.51% | -14.24% | ||||||||||
| Vyxeos | 160.12M | 162.60M | 156.26M | 151.77M | 142.82M | 147.50M | 130.85M | 131.09M | ||||||||||
| Vyxeos Growth | 12.11% | 10.24% | 19.42% | 15.78% | 9.09% | 15.25% | -1.23% | -4.38% |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xywav | 1.50B | 1.47B | 1.41B | 1.35B | 1.31B | 1.27B | 1.22B | 1.14B | ||||||||||
| Xywav Growth | 14.67% | 15.73% | 15.77% | 18.46% | 24.80% | 32.82% | 41.60% | 50.85% | ||||||||||
| Epidiolex | 991.44M | 972.42M | 938.00M | 900.15M | 855.28M | 845.47M | 811.84M | 794.35M | ||||||||||
| Epidiolex Growth | 15.92% | 15.02% | 15.54% | 13.32% | 11.45% | 14.81% | 12.26% | 15.57% | ||||||||||
| Xyrem | 206.83M | 233.82M | 291.25M | 358.24M | 455.83M | 569.73M | 710.51M | 841.43M | ||||||||||
| Xyrem Growth | -54.63% | -58.96% | -59.01% | -57.42% | -52.07% | -44.17% | -33.08% | -24.40% | ||||||||||
| Sativex | 21.55M | 18.88M | 18.84M | 18.88M | 15.31M | 19.67M | 19.25M | 17.85M | ||||||||||
| Sativex Growth | 40.80% | -4.02% | -2.13% | 5.81% | -20.21% | 16.90% | 14.92% | -9.09% |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.